2022
DOI: 10.1016/j.csbj.2022.01.026
|View full text |Cite
|
Sign up to set email alerts
|

Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
37
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 60 publications
(37 citation statements)
references
References 192 publications
(186 reference statements)
0
37
0
Order By: Relevance
“…The knowledge of COVID-19 has increased greatly with the in-depth study, which give a boost to the continuous development of candidate drugs in COVID-19 treatment. For instance, several original findings on the pathogenesis of COVID-19 reported by Chinese researchers indicated that some inhibitors of signaling pathways may also be used in combating SARS-CoV-2 125 , 126 , 127 , 128 . It was reported that SARS-CoV-2 N protein is a key mediator for acute kidney injury (AKI), which can induce AKI via the Smad3-dependent G1 cell cycle arrest mechanism 127 .…”
Section: Discussionmentioning
confidence: 99%
“…The knowledge of COVID-19 has increased greatly with the in-depth study, which give a boost to the continuous development of candidate drugs in COVID-19 treatment. For instance, several original findings on the pathogenesis of COVID-19 reported by Chinese researchers indicated that some inhibitors of signaling pathways may also be used in combating SARS-CoV-2 125 , 126 , 127 , 128 . It was reported that SARS-CoV-2 N protein is a key mediator for acute kidney injury (AKI), which can induce AKI via the Smad3-dependent G1 cell cycle arrest mechanism 127 .…”
Section: Discussionmentioning
confidence: 99%
“…The drug is approved in many countries for RA, Castleman’s disease and juvenile idiopathic arthritis, and is also expected to have therapeutic effects on giant cell arteritis, polymyalgia rheumatica, and large-vessel vasculitis [ 48 ]. Tocilizumab was also approved for severe COVID-19 treatment by the EMA in 2021 [ 49 ].…”
Section: Tocilizumabmentioning
confidence: 99%
“…In cells with high transmembrane protease serines 2 (TMPRSS2) expression (e.g. Calu-3, a human Lung Cancer Cell Line which is with high TMPRSS2 expression but deficiency in cathepsin L), SARS-CoV-2 enter into cells by membrane fusion-mediated infection after TMPRSS2 cleaves S protein into S1 and S2 subunits ( 54 , 55 ), and binds with S2 subunit ( 55 , 56 ). In cells with low TMPRSS2 expression (e.g.…”
Section: Sars-cov-2 Rna Positive In Breastmilk But Without Infectious...mentioning
confidence: 99%
“…In cells with low TMPRSS2 expression (e.g. Vero E6, an African green monkey kidney cell line), SARS-CoV-2 enters into cells via the endocytosis route to form endosome, and SARS-CoV-2 genomic RNA are released from endosome into cytoplasm directly with the assistance of cathepsin L (CTSL) ( 55 , 56 ) ( Figure 1 ). And in human primary lung epithelial cells or human colorectal adenocarcinoma epithelial cell line Caco-2, both routes are utilized for SARS-CoV-2 entry ( 57 59 ).…”
Section: Sars-cov-2 Rna Positive In Breastmilk But Without Infectious...mentioning
confidence: 99%